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ORIGINAL ARTICLE

Metachronous second primary malignancy in head and neck cancer
patients: is five years of follow-up sufficient?
Mohammad Adeel1, Moghira Iqbal Siddiqi2
1
Department of Surgical Oncology, Section of Head and Neck Oncology, Shaukat Khanum Memorial Cancer Hospital, Lahore,
2
Department of Otolaryngology & Head and Neck Surgery, The Aga Khan University Hospital, Karachi, Pakistan

Abstract (J Korean Assoc Oral Maxillofac Surg 2018;44:220-224)
Objectives: The aim of this study was to determine the incidence and characteristics of second primary malignancy (SPM) in patients with head and
neck squamous cell carcinoma treated at a tertiary care hospital.
Materials and Methods: We retrospectively reviewed the medical records of 221 patients who underwent surgery with or without adjuvant treatment for head and neck cancer from 2000 to 2002. Data of age, sex, risk factors, sites of primary and SPM, TNM stage of primary tumor, incidence of
SPM, and survival were collected from medical charts.
Results: Eighteen patients developed SPM during a median follow-up of 67 months, with an overall incidence of 8.14%. In addition, 77.7% of SPMs
occurred in the oral cavity, followed by 11% in the lungs. The 5-year overall survival after the diagnosis of SPM in the head or neck was 70%, compared to 30% for SPM in other body regions.
Conclusion: Considering a high incidence of SPM, i.e., 8.14%, in a mean follow-up period of 67 months suggests the need for long-term follow-up.
Since treatment of SPM has shown an acceptable survival rate, early detection and curative therapy should be emphasized.
Key words: Second primary malignancy, Survivorship, Survival rate
[paper submitted 2017. 10. 30 / revised 2017. 12. 17 / accepted 2018. 3. 2]

I. Introduction
Head and neck cancer patients are declared tumor-free after surgery alone or with adjuvant treatment. Most reputable
centers advocate a follow-up plan that emphasizes a monthly
visit in the first year, bimonthly in the second year, quarterly
in the third year, and every six months in the fifth year of
survivorship1. After five years of survivor-ship, the patient
is considered disease-free. We follow the patients up to five
years, and then no follow-ups are recommended unless needed. Recent literature showed that up to 24% of head and neck
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cancer patients will develop a second primary lesion2. The
incidence of second primary malignancy (SPM) was mostly
found in patients who continued to consume carcinogenic
agents and/or smoking3.
Locoregional control of head and neck cancer has improved in the last couple of decades; however, long-term
survival has shown minimal improvement due to distant
metastasis and SPM4,5. All SPMs have been shown to have a
significant impact on survival6. In Pakistan, this critical issue
has not been addressed in any study to date. We hypothesize
based on anecdotal data that incidence of SPM in our population could be higher than in Western populations. Hence, we
retrospectively reviewed our patients over a defined period
to determine the incidence of SPM and patient outcomes in
terms of survival.

II. Materials and Methods
In the present study, the files of 221 newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC)
who underwent surgery with or without adjuvant therapy at
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The Aga Khan University Hospital from January 2000 to
December 2002 were retrospectively reviewed. Of these,
18 patients developed SPM during the follow-up period and
composed our study cohort.
Patients who were inoperable, underwent surgery outside of
our hospital, or refused primary surgery were excluded from
the study. All patients had a minimum of 10 years of followup at the time of data collection. Since this study consisted
only of patient chart review, according to institutional policy,
exemption was granted by the Ethical Review Committee of
The Aga Khan University Hospital (2601-Sur-ERC-13).
SPM was defined using the criteria established by Warren7 and Hong et al.8, who stated that the tumors should be
histologically malignant and at least 2 cm apart or developed
at least 3 years after the original tumor. In addition, any new
malignancy of the lung should be considered SPM if it is a
single lesion and histologically different, and the possibility
of metastatic carcinoma has been excluded, unless the tumor
occurred after 3 years, which classifies it a SPM based on the
above definition. Tumors were also classified as synchronous
or metachronous: a synchronous tumor was defined as occurring within 6 months after the diagnosis of primary tumor,
and metachronous malignancy was defined as occurring after
6 months of follow-up.
All patients had a complete medical history taken and head
and neck examination performed on every outpatient followup. Chest x-rays were performed annually; other complementary examinations were performed based on symptoms and
clinical findings.
All patients that fulfilled the inclusion criteria were included in the study. Files were reviewed and Performa were filled.
Follow-ups were recorded for all patients, and incidence was
determined in terms of frequency/percentage. Survival was
calculated using the Kaplan-Meier curve. Data were analyzed
using IBM SPSS Statistics (ver. 20; IBM Co., Armonk, NY,
USA).

III. Results
The demographic data of patients and primary tumorrelated details are shown in Table 1. A total of 18 patients was
included in our study. The median age was 53.5±12.0 years.
Twelve patients (66.7%) were male and six were female. All
patients had some type of addiction such as tobacco or betel
nut. Most common site of primary tumor was the oral cavity and was observed in 15 patients (83.3%). We performed
pathological staging of the primary tumor using American

Joint Committee on Cancer staging system seventh edition9;
8 patients (44.4%) had stage IV disease, and stage II disease
was observed in 7 individuals (38.9%).
All patients underwent surgery as their primary treatment
modality, and eight patients received adjuvant radiotherapy.
All patients participated in regular follow-up. Median time
to SPM occurrence was 67 months. Sixteen of 18 patients
developed SPM in the head and neck, whereas only two patients developed SPM in a non-head and neck site. Of the 16
patients with SPM in the head and neck, 14 were treated surgically, whereas two had treatment with non-surgical modality with curative intent.
The overall incidence of SPM was 8.14%, as shown in
Table 2. In patients who developed SPM in the head and neck
area, oral cavity was the most common site, observed in 14
patients (77.8%).(Table 3) However, larynx and oral cavity
were each also a site of SPM.
Kaplan-Meier curve was used to determine the 5-year and
10-year survival rates (Fig. 1); approximately 70% at 5 years
and gradually declined to 38% at 10 years for all head and

Table 1. Characteristics of patients with second primary malignancy
Characteristic
Gender
Male
Female
Median age (yr)
Addiction
Tobacco
Betel nut
More than one
Primary tumor site
Oral cavity
Hypopharynx
Larynx
Primary pathologic T stage
T1
T2
T3
T4
Primary pathologic N stage
N0
N1
N2
N3
Primary pathologic stage
Stage I
Stage II
Stage III
Stage IV

Value
12 (66.7)
6 (33.3)
53.5±12.0
6 (33.3)
8 (44.4)
4 (22.2)
15 (83.3)
2 (11.1)
1 (5.6)
1 (5.6)
8 (44.4)
2 (11.1)
7 (38.9)
14 (77.8)
2 (11.1)
2 (11.1)
0
1 (5.6)
7 (38.9)
2 (11.1)
8 (44.4)

Values are presented as number (%) or mean±standard deviation.
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Table 2. Characteristics of second primary tumor

1.0

Characteristic

0.8

8.14
3.6
4.5
67 (0-121)
16 (88.9)
2 (11.1)
2 (11.1)
3 (16.7)
7 (38.9)
4 (22.2)
70
30

(SPM: second primary malignancy)
Values are presented as %, median (range), or number (%).
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Table 3. Second primary malignancy sites
Site

Value

Head and neck
Oral cavity
Oropharynx
Hypopharynx
Larynx
Non-head and neck
Lung
Esophagus

14 (77.8)
1 (5.6)
0
1 (5.6)
2 (11.1)
-

Values are presented as number (%).
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neck SPMs.

IV. Discussion
Although locoregional control of HNSCC has improved
in the last few decades, SPM and distant metastasis are still
important aspects that limit survival10,11. Vikram et al.6 reported failure patterns of HNSCC, revealing that SPM and
distant metastasis mostly occurred in the first 2 to 3 years of
primary treatment, after which the incidence of distant metastasis decreased with time12. Conversely, the incidence of
SPM remained static over time13,14. The data from developing
countries have consistently demonstrated a lower frequency
of SPMs, which could be attributed to the limited number
of studies published; Mehdi et al.15 reported an incidence of
1.14%, compared to an incidence of 10% to 40% in previous
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Cumulative survival

Incidence of SPM (%)
Overall
5-year SPM rate
10-year SPM rate
Time interval (mo)
Site of SPM
Head and neck
Non-head and neck
Pathologic stage of SPM (head and neck)
Stage I
Stage II
Stage III
Stage IV
5-year survival rate (%)
Head and neck
Non-head and neck

Value

0.6
0.4
0.2

Site of SPM
Head and neck
Non-head and neck

0.0
0.00

25.00

50.00

75.00

100.00

125.00

Follow-up

Fig. 1. Survival functions. (SPM: second primary malignancy)
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studies14,16,17. In the present study, the overall incidence was
8.14%, which was comparable with international data.
The theory of field cancerization was first introduced by
Slaughter and his colleagues in 1953, and refers to continuous
exposure of the upper aerodigestive tract to carcinogens that
may result in multiple precancerous changes and potentially
lead to a malignant change. Patients using alcohol and tobacco have been shown to have the greatest risk for SPMs11,13. In
Asians, betel quid chewing is also a risk factor for SPM18. In
the present study, all patients were using tobacco, betel quid,
or both. However, none of the patients used alcohol, which
could be a limitation due to cultural restraints; the majority
of patients may be hesitant to admit consuming alcohol. Because of the retrospective nature of this study, exact details
of continued addictions after treatment of the primary malignancy could not be confirmed.
Reportedly, the most common site of SPM is the head and
neck, followed by lungs and esophagus14,19. Hsu et al.20 in
their study of 18 patients with a SPM showed that 70.2% of
SPMs developed in the head and neck, whereas 27.7% occurred in non-head and neck sites. Similarly, in our study, the
most frequent location of SPM was head and neck (89%), followed by lungs (11%). The median time interval to develop
a SPM in the present study was 67 months, and other studies
have reported a median time interval of 48 to 72 months1,20.
Furthermore, in our study, the 5-year survival in patients
with head and neck SPM was 70% and was comparable with
other reports1,21. Similarly, in a previous study, a 10-year
survival of 39% was reported1, which was nearly in agreement with the results from our study (38%). The decline in
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survival observed in long-term follow-up can be attributed to
the development of SPM; the median time to develop another
tumor was 67 months.
Patients with SPM have a relatively long-term survival,
and many patients do well considering it is their second tumor. Therefore, efforts should be made to implement regular
follow-ups for early diagnosis13. In our study, many patients
were diagnosed when they were not monitored because
they had completed their 5 years of follow-up. We suggest
that treated head and neck cancer patients be followed up
throughout their lives to detect early SPMs, which should be
treated aggressively to attain maximum benefit. Despite the
better outcomes observed in this study, multi-institutional
data are required to confirm the results.
In our report, a series of patients was surgically treated for
HNSCC in a single tertiary care hospital. This study had several strengths and limitations. The main strength of the study
was that all patients with HNSCC in a given period were primarily treated with surgery. Secondly, because patients were
primarily treated with surgery, the impact of radiation on development of SPM was minimized. Conversely, study limitations include the retrospective study design, missing records,
and small sample size.

V. Conclusion
Based on SPM patterns, we suggest that patients with previously treated HNSCC should receive long-term follow-up
for early detection of SPM. Although the 10-year survival
decreases by 50% due to development of SPM, an acceptable
survival rate can still be achieved by early detection of SPM
with regular long-term follow-up and appropriate subsequent
curative therapy.
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